Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights
09 nov. 2021 16h05 HE
|
Inozyme Pharma Inc.
– On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety data in the first half of 2022 – – Cash,...
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting
04 oct. 2021 07h30 HE
|
Inozyme Pharma Inc.
- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets - - Preclinical data...
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
22 sept. 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of...
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
11 août 2021 06h00 HE
|
Inozyme Pharma Inc.
- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency – – Clinical Trial Application in Europe accepted for Phase 1/2 trial of...
Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
04 août 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency
21 juil. 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources
13 juil. 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency
09 juin 2021 07h30 HE
|
Inozyme Pharma Inc.
- Clinical trial initiation expected in mid-2021 –- Preliminary safety and biomarker data expected by the end of 2021 - BOSTON, June 09, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq:...
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights
12 mai 2021 06h00 HE
|
Inozyme Pharma Inc.
– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting...
Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency
07 mai 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...